Pr. Christophe Hirtz has been working on Clinical Proteomics since 2000 and was one of the first researchers to explore the complexity of the human salivary proteome (Hirtz et al., 2005) using mass spectrometry. Since then, he has specialized in clinical assays and R&D activities in the field of clinical proteomics and neurodegenerative diseases since 2010. He is recognized as an expert in high-resolution proteomics for the identification and quantification of biomarkers (Bottom-up/Top-down), in targeted mass spectrometry for multiplexed and absolute quantification of biomarkers, and in multiplexed and ultra-sensitive immunodetection. He is currently responsible for the Clinical Proteomics Platform of Montpellier
Hospital and Montpellier University, part of the Shimadzu European Innovation Center and considered as a key opinion in the field of clinical mass spectrometry and clinical biomarkers. Since 2024, he has been the coordinator of an ANR (Moneskin, 550 K€) in collaboration with Pierre Fabre. He has published 160 international scientific articles (H factor: 36, >5500 citations, 3 international patents).
Pr. Christophe Hirtz has been working on Clinical Proteomics since 2000 and was one of the first researchers to explore the complexity of the human salivary proteome (Hirtz et al., 2005) using mass spectrometry. Since then, he has specialized in clinical assays and R&D activities in the field of clinical proteomics and neurodegenerative diseases since 2010. He is recognized as an expert in high-resolution proteomics for the identification and quantification of biomarkers (Bottom-up/Top-down), in targeted mass spectrometry for multiplexed and absolute quantification of biomarkers, and in multiplexed and ultra-sensitive immunodetection. He is currently responsible for the Clinical Proteomics Platform of Montpellier
Hospital and Montpellier University, part of the Shimadzu European Innovation Center and considered as a key opinion in the field of clinical mass spectrometry and clinical biomarkers. Since 2024, he has been the coordinator of an ANR (Moneskin, 550 K€) in collaboration with Pierre Fabre. He has published 160 international scientific articles (H factor: 36, >5500 citations, 3 international patents).